US FDA plans November meeting to implement biosimilars approval pathway
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is planning a two-day public meeting to gather feedback from stakeholders on ways to implement a biosimilars approval pathway, the legal framework for which was passed by Congress earlier this year as part of the healthcare reform legislation.